CGH
ITCI

Crossmark Global Holdings’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Crossmark Global Holdings’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,603
Closed -$211K – 1375
2025
Q1 		$211K Buy
+1,603
New +$200K ﹤0.01% 1245
2024
Q3 		– Sell
-4,652
Closed -$319K – 1363
2024
Q2 		$319K Sell
4,652
-1,520
-25% -$105K 0.01% 1041
2024
Q1 		$427K Sell
6,172
-2,027
-25% -$139K 0.01% 938
2023
Q4 		$587K Hold
8,199
– – 0.01% 779
2023
Q3 		$445K Buy
8,199
+533
+7% +$31.1K 0.01% 867
2023
Q2 		$466K Buy
7,666
+10
+0.1% +$623 0.01% 887
2023
Q1 		$415K Sell
7,656
-6
-0.1% -$290 0.01% 907
2022
Q4 		$405K Buy
7,662
+685
+10% +$34.3K 0.01% 880
2022
Q3 		$325K Buy
6,977
+1,027
+17% +$53.6K 0.01% 955
2022
Q2 		$340K Buy
+5,950
New +$337K 0.01% 978

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Crossmark Global Holdings's ITCI Position: Q2 2025 in Review

Crossmark Global Holdings sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,603 shares — an estimated $211K sold.

Crossmark Global Holdings first reported a position in ITCI in Q2 2022 and held it in 10 quarters. The position peaked at $587K in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Crossmark Global Holdings reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Crossmark Global Holdings sold 1,603 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $211K.
  • Crossmark Global Holdings first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 10 quarters.
  • Crossmark Global Holdings's Intra-Cellular Therapies Inc. position peaked at $587K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Crossmark Global Holdings's 13F filing for Q2 2025, filed 8 Aug 2025.